期刊文献+

NOK与FGFR2在非小细胞肺癌中的表达及临床意义 被引量:1

Expressions of NOK and FGFR2 in non-small cell lung cancer and their clinical significance
下载PDF
导出
摘要 目的检测含激酶结构域新原癌基因(NOK)与成纤维细胞生长因子受体2(FGFR2)在非小细胞肺癌(NSCLC)中的表达,分析其在不同病理类型、病理分级及临床TNM分期之间的表达差异及相关性。方法应用免疫组化En Vision法检测NOK与FGFR2在163例NSCLC组织中的表达,分析其表达与病理类型、临床TNM分期、病理分级之间的关系,以及NOK与FGFR2表达的相关性。结果 NOK、FGFR2在163例NSCLC组织中的阳性表达率分别为66.7%和85.2%。NOK在肺鳞癌和肺腺癌中的阳性表达率分别为64.5%和72.6%,差异无统计学意义(P>0.05);NOK在不同TNM分期之间及在不同病理分级之间的表达差异均有统计学意义(P=0.000)。FGFR2在肺鳞癌和肺腺癌中的阳性表达率分别为88.6%和85.7%,差异无统计学意义(P>0.05);FGFR2在不同TNM分期之间及在不同病理分级之间的表达差异均有统计学意义(P<0.05)。NOK与FGFR2蛋白表达在NSCLC(r=0.640,P=0.000)、肺鳞癌(r=0.684,P=0.000)、肺腺癌(r=0.597,P=0.000)组织中均呈正相关。结论 NOK与FGFR2在NSCLC中高表达,其表达与病理类型、病理分级及TNM分期有关,提示二者可能与NSCLC的发生和发展有关。 Objective To detect the expressions of novel oncogene with kinase-domain(NOK) and fibroblast growth factor receptor 2 (FGFR2) protein in non-small cell lung cancer(NSCLC),and analyze the expressions among different pathological types,pathological grades,TNM stages and their correlation.Methods The expressions of NOK and FGFR2 protein were detected with immunohistochemical En Vision method in 163 NSCLC samples,the expressions among different pathological types,pathological grades,TNM stages and the correlation between expressions of NOK and FGFR2 in tumor samples were analyzed.Results The positive rate of NOK and FGFR2 protein in 163 NSCLC tissues were 66.7% and 85.2%,respectively.The positive rate of NOK protein in lung squamous cell carcinoma and adenocarcinoma were 64.5% and 72.6% with no statistical difference (P 〉 0.05).NOK protein was expressed among different TNM stages with statistical difference(P =0.000),and the expressions also different in pathological grades(P=0.000).The positive rate of FGFR2 protein in lung squamous cell carcinoma and adenocarcinoma were 88.6% and 85.7% with no statistical difference(P 〉0.05).The expression of FGFR2 protein at different TNM stages and different pathological grades were also different statistically(P =0.000).The positive correlation between NOK and FGFR2 expression was found in NSCLC samples (r =0.640,P =0.000),squamous cell carcinoma(r =0.684,P =0.000) and adenocarcinoma(r =0.597,P =0.00).Conclusion NOK and FGFR2 protein are highly expressed in NSCLC,and their expressions correlates with pathological types,pathological grades and TNM stages,which may be related to the occurrence and development of NSCLC.
出处 《临床肿瘤学杂志》 CAS 2013年第12期1071-1075,共5页 Chinese Clinical Oncology
关键词 非小细胞肺癌 含激酶结构域新原癌基因(NOK) 成纤维细胞生长因子受体2(FGFR2) Non-small cell lung cancer(NSCLC) Novel oncogene with kinase-domain(NOK) Fibroblast growth factor receptor 2 (FGFR2)
  • 相关文献

参考文献4

二级参考文献85

  • 1Liu L, Yu XZj Li TSj et al. A novel protein tyrosine kinase NOK that shares homology with platelet-derived growth factor/fibroblast growth factor receptors induces tumorigenesis and metastasis in nude mice. Cancer Res, 2004, 64(10): 3491-3499.
  • 2Amachikal T, Kobayashil D, Moriai R, et al. Diagnostic relevance of over- expressed mRNA of novel oncogene with kinase-domain (NOK) in lung cancers. Lung Cancer, 2007, 56(3): 337-340.
  • 3Moriai R, Kobayashi D, Amachika T, et al. Diagnostic relevance of over- expressed NOK mRNA in breast cancer. Anticancer Res, 2006, 26(6): 4969-4973.
  • 4Li YH, Zhong S, Rong ZL, et al. The carboxyl terminal tyrosine 417 residue of NOK has an autoinhibitory effect on NOK-mediated signaling transductions. Biochem Biophys Res Commun, 2007, 356(2): 444-449.
  • 5Kimbro KS, Duschene K, willard M, et al. A novel gene STYK1/NOK is upregulated in estrogen receptor-alpha negative estrogen receptor-beta positive breast cancer cells following estrogen treatment. Mol Biol Rep, 2008, 35(1): 23-27.
  • 6Grose R, Dickson C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev, 2005,16 : 179-186.
  • 7Sato M, Kitazawa T, Iwai T, et al. Isolation of chicken-bek and a related gene ; identification of structural variation in the ligand-binding domains of the FGF-receptor family. Oncogene, 1991,6:1279-1283.
  • 8Szebenyi G, Fallon JF. Fibroblast growth factors as multifunctional signaling factors. Int Rev Cyrol, 1999,185:45-106.
  • 9Cho K, Ishiwata T, Naito Z, et al. New therapeutic strategy for intractable pancreatic cancer and its fundamental research. J Nippon Med Sch, 2010,77:62-63.
  • 10Kondo T, Zhu X, Asa SL, et al. The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer. Clin Cancer Res, 2007,13:4713-4720.

共引文献15

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部